Semaglutide's kidney protection extends beyond CKD trials

Design

Prespecified participant-level pooled analysis of three placebo-controlled RCTs

Population

30,787 people with CKD or atherosclerotic disease, with or without diabetes

Primary outcome

Kidney composite including cardiovascular death

Effect

HR 0.84 (95% CI 0.77–0.91); kidney-only composite HR 0.80 (0.69–0.92)

A prespecified participant-level pooled analysis in The Lancet Diabetes & Endocrinology combined three placebo-controlled semaglutide trials: FLOW (people with type 2 diabetes and CKD, 1.0 mg weekly), SELECT (atherosclerotic disease and overweight without diabetes, 2.4 mg weekly) and SOUL (type 2 diabetes with atherosclerotic disease or CKD, oral 14 mg daily). In total 30,787 participants were followed for about 3.3 to 4 years.

The primary kidney composite — sustained 50% eGFR decline, kidney failure, kidney death or cardiovascular death — occurred in 973 people on semaglutide and 1,134 on placebo (HR 0.84). The narrower kidney-only composite, without cardiovascular death, gave HR 0.80. Safety was in line with other GLP-1 receptor agonist trials.

FLOW already established a kidney benefit in diabetic CKD. The pooled data suggest the effect is present across a wider cardio-kidney-metabolic population, including people without diabetes, and across oral and injected forms. The authors note the trials differed in population, dose and route, and the analysis was funded by the manufacturer.

For a patient with type 2 diabetes and either CKD or atherosclerotic disease, kidney protection is now a further reason to choose a GLP-1 receptor agonist with proven outcomes, alongside an SGLT2 inhibitor rather than instead of one.

• Count kidney protection as a reason to prescribe semaglutide in type 2 diabetes with CKD or atherosclerotic disease
• Keep the SGLT2 inhibitor; these trials added semaglutide to standard care
• Check eGFR and urine albumin-to-creatinine ratio before starting and at follow-up
• Do not prescribe semaglutide for kidney protection alone in people without diabetes on this evidence; that remains outside guidelines

Why it matters

Semaglutide's kidney benefit no longer rests on a single CKD trial.

Don't overread it

The kidney-only benefit in people without diabetes comes from pooling, not from a trial designed to test it.

The statistics, in plain English

An HR of 0.84 means a 16% lower rate of the composite; the interval 0.77–0.91 stays well below 1, so chance is an unlikely explanation. Part of the primary composite is cardiovascular death, which is why the kidney-only result (HR 0.80, 0.69–0.92) is the cleaner read of a kidney effect.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.